Description
Ramucirumab (KDR/CD309) Antibody, Monoclonal | 10-311 | Gentaur UK, US & Europe Distribution
Host: N/A
Reactivity: N/A
Homology: N/A
Immunogen: Homo sapiens / KDR/CD309 [Homo sapiens]
Research Area: Drug Analogues
Tested Application: N/A
Application: N/A
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: >95%
Clonality: Monoclonal
Clone: N/A
Isotype: IgG1-kappa
Conjugate: Unconjugated
Physical State: N/A
Buffer: PBS buffer pH7.5
Concentration: N/A
Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.
Alternate Name: 1121B, IMC-1121B, LY3009806
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2) , a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D) , thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.